Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares traded -3.29% lower at $8.66 on Wall Street last session.
In accordance with the data, 8 analysts cover Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $8.00, we find $11.50. Given the previous closing price of $8.95, this indicates a potential upside of 28.49 percent. RXRX stock price is now 39.59% away from the 50-day moving average and -1.22% away from the 200-day moving average. The market capitalization of the company currently stands at $1.42B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 5 analysts and a buy by 3. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
In other news, Borgeson Blake, Director sold 8,885 shares of the company’s stock on May 16. The stock was sold for $45,241 at an average price of $5.09. Upon completion of the transaction, the Director now directly owns 7,549,632 shares in the company, valued at $65.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 03, Chief Executive Officer Gibson Christopher sold 33,073 shares of the business’s stock. A total of $155,761 was realized by selling the stock at an average price of $4.71. This leaves the insider owning 953,225 shares of the company worth $8.25 million. Insiders disposed of 487,832 shares of company stock worth roughly $4.22 million over the past 1 year. A total of 5.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RXRX stock. A new stake in Recursion Pharmaceuticals Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $4,452,000. D. E. SHAW & CO., INC. invested $1,757,000 in shares of RXRX during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in Recursion Pharmaceuticals Inc. valued at approximately $1,458,000. JUMP FINANCIAL, LLC acquired a new stake in RXRX for approximately $1,122,000. PROFUND ADVISORS LLC purchased a new stake in RXRX valued at around $617,000 in the second quarter. In total, there are 225 active investors with 68.70% ownership of the company’s stock.
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) opened at $9.34 on Thursday. During the past 12 months, Recursion Pharmaceuticals Inc. has had a low of $4.54 and a high of $14.18. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.30, and a quick ratio of 5.30. The fifty day moving average price for RXRX is $6.23 and a two-hundred day moving average price translates $8.77 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) was released for Mar, 2023. The company reported revenue of $12.13 million for the quarter, compared to $5.33 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 127.53 percent.
Recursion Pharmaceuticals Inc.(RXRX) Company Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
